Use of human monoclonal antibodies to treat Chikungunya virus infection.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23125446.
- Also identified by DOI 10.1093/infdis/jis674.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chikungunya virus (CHIKV) is an alphavirus prevalent in tropical regions. It causes an acute febrile disease that, in elderly individuals and newborns, is often associated with severe complications. We previously reported the isolation and characterization of 2 human monoclonal antibodies neutralizing CHIKV in vitro: 5F10 and 8B10. Here, we tested their efficacy in vivo as prophylactic and therapeutic treatments of CHIKV infection in AGR129 mice. In both settings, 5F10 and 8B10 were able to significantly delay CHIKV-driven lethality. Our results support the development of prophylactic and therapeutic treatments for CHIKV infection, using a combination of 5F10 and 8B10.
Medical subject headings
- Alphavirus Infections
- Antibodies, Monoclonal
- Chikungunya virus